Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 10/2018

01-10-2018 | Review Article

Primary leiomyosarcoma of the skin: a comprehensive review on diagnosis and treatment

Authors: Martina Zacher, Markus V. Heppt, Titus J. Brinker, Kinan M. Hayani, Michael J. Flaig, Carola Berking

Published in: Medical Oncology | Issue 10/2018

Login to get access

Abstract

Sarcomas are a heterogeneous group of mesenchymal tumors which can affect bone and soft tissue. Leiomyosarcoma (LMS) is a rare subtype localized to the skin or subcutaneous tissue. Due to the heterogeneity of sarcomas, reviews and guidelines with an in-depth focus specifically on primary LMS of the skin are sparse. This article is intended to provide an up to date and systematic overview on diagnosis, treatment, and surveillance of this rare entity to provide a framework for decision making and management for dermato-oncologists. We discuss novel treatment options for advanced disease such as targeted therapy with kinase inhibitors and immune checkpoint blockade which may improve the prognosis even in advanced stages of LMS.
Literature
1.
Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol. 1997;24(5):504–14.PubMed
2.
3.
4.
Holst VA, Junkins-Hopkins JM, Elenitsas R. Cutaneous smooth muscle neoplasms: Clinical features, histologic findings, and treatment options. J Am Acad Dermatol. 2002;46(4):477–90. quiz, 491 – 474.CrossRefPubMed
5.
6.
Kohlmeyer J, Steimle-Grauer SA, Hein R. Cutaneous sarcomas. J Dtsch Dermatol Ges. 2017;15(6):630–48.PubMed
7.
Deneve JL, Messina JL, Bui MM, Marzban SS, Letson GD, Cheong D, et al. Cutaneous leiomyosarcoma: Treatment and outcomes with a standardized margin of resection. Cancer Control. 2013;20(4):307–12.CrossRefPubMedPubMedCentral
8.
Fields JP, Helwig EB. Leiomyosarcoma of the skin and subcutaneous tissue. Cancer. 1981;47(1):156–69.CrossRefPubMed
9.
Phelan JT, Sherer W, Mesa P. Malignant smoothmuscle tumors (leiomyosarcomas) of soft-tissue origin. N Engl J Med. 1962;266:1027–30.CrossRefPubMed
10.
Dahl I, Angervall L. Cutaneous and subcutaneous leiomyosarcoma. A clinicopathologic study of 47 patients. Pathol Eur. 1974;9(4):307–15.PubMed
11.
Jensen ML, Jensen OM, Michalski W, Nielsen OS, Keller J. Intradermal and subcutaneous leiomyosarcoma: A clinicopathological and immunohistochemical study of 41 cases. J Cutan Pathol. 1996;23(5):458–63.CrossRefPubMed
12.
Farran Y, Padilla O, Chambers K, Philipovskiy A, Nahleh Z. Atypical presentation of radiation-associated breast angiosarcoma: A case report and review of literature. Am J Case Rep. 2017;18:1347–50.CrossRefPubMedPubMedCentral
13.
Sabater-Marco V, Ferrando-Roca F, Morera-Faet A, Garcia-Garcia JA, Bosch SB, Lopez-Guerrero JA. Primary cutaneous leiomyosarcoma arising in a patient with li-fraumeni syndrome: A neoplasm with unusual histopathologic features and loss of heterozygosity at tp53 gene. Am J Dermatopathol. 2018;40(3):225–7.CrossRefPubMed
14.
Gao P, Seebacher NA, Hornicek F, Guo Z, Duan Z. Advances in sarcoma gene mutations and therapeutic targets. Cancer Treat Rev. 2018;62:98–109.CrossRefPubMed
15.
Aneiros-Fernandez J, Antonio Retamero J, Husein-Elahmed H, Ovalle F, Aneiros-Cachaza J. Primary cutaneous and subcutaneous leiomyosarcomas: Evolution and prognostic factors. Eur J Dermatol. 2016;26(1):9–12.PubMed
16.
Patt JC, Haines N. Soft tissue sarcomas in skin: Presentations and management. Semin Oncol. 2016;43(3):413–8.CrossRefPubMed
17.
Corcoran S, Hogan AM, Nemeth T, Bennani F, Sullivan FJ, Khan W, et al. Isolated cutaneous metastasis of uterine leiomyosarcoma: Case report and review of literature. Diagn Pathol. 2012;7:85.CrossRefPubMedPubMedCentral
18.
Zarcone N, Ciacci A, Di Gregorio C, Rivasi F. [subcutaneous metastasis of uterine leiomyosarcoma]. Minerva Ginecol. 1988;40(8):489–91.PubMed
19.
Vandergriff T, Krathen RA, Orengo I. Cutaneous metastasis of leiomyosarcoma. Dermatol Surg. 2007;33(5):634–7.PubMed
20.
Soipi S, Vucic M, Ulamec M, Tomas D, Kruslin B, Spajic B. Leiomyosarcoma of the spermatic cord with scalp metastasis: Case report and literature review. Coll Antropol. 2014;38(2):763–6.PubMed
21.
Alessi E, Innocenti M, Sala F. Leiomyosarcoma metastatic to the back and scalp from a primary neoplasm in the uterus. Am J Dermatopathol. 1985;7(5):471–6.CrossRefPubMed
22.
Annest NM, Grekin SJ, Stone MS, Messingham MJ. Cutaneous leiomyosarcoma: A tumor of the head and neck. Dermatol Surg. 2007;33(5):628–33.PubMed
23.
Bernstein SC, Roenigk RK. Leiomyosarcoma of the skin. Treatment of 34 cases. Dermatol Surg. 1996;22(7):631–5.CrossRefPubMed
24.
Banuls J, Botella R, Sevila A, Aranda I, Roman P. Leiomyosarcoma of the upper lip. Int J Dermatol. 1994;33(1):48–9.CrossRefPubMed
25.
Piana M, Martinez Mansur R, Codone J, Elizalde F, Diez M, Reyes E, et al. [penile leiomyosarcoma: Case report and bibliographic review]. Arch Esp Urol. 2006;59(7):728–31.CrossRefPubMed
26.
27.
Rabinovich J. Leiomyosarcoma of the foreskin: A rare case of mesenchymal foreskin tumor. Urologe A. 2018;57(5):591–3.CrossRefPubMed
28.
John T, Portenier D, Auster B, Mehregan D, Drelichman A, Telmos A. (2006). Leiomyosarcoma of scrotum–case report and review of literature. Urology. 67(2):424 e413–424 e415.CrossRef
29.
Lo Muzio L, Favia G, Farronato G, Piattelli A, Maiorano E. Primary gingival leiomyosarcoma. A clinicopathological study of 1 case with prolonged survival. J Clin Periodontol. 2002;29(2):182–7.CrossRefPubMed
30.
Kaltreider SA, Destro M, Lemke BN. Leiomyosarcoma of the orbit. A case report and review of the literature. Ophthalmic Plast Reconstr Surg. 1987;3(1):35–41.CrossRefPubMed
31.
32.
33.
34.
35.
Hashimoto H, Daimaru Y, Tsuneyoshi M, Enjoji M. Leiomyosarcoma of the external soft tissues. A clinicopathologic, immunohistochemical, and electron microscopic study. Cancer. 1986;57(10):2077–88.CrossRefPubMed
36.
Winchester DS, Hocker TL, Brewer JD, Baum CL, Hochwalt PC, Arpey CJ, et al. Leiomyosarcoma of the skin: Clinical, histopathologic, and prognostic factors that influence outcomes. J Am Acad Dermatol. 2014;71(5):919–25.CrossRefPubMed
37.
38.
39.
Massi D, Franchi A, Alos L, Cook M, Di Palma S, Enguita AB, et al. Primary cutaneous leiomyosarcoma: Clinicopathological analysis of 36 cases. Histopathology. 2010;56(2):251–62.CrossRefPubMed
40.
Luke JJ, Keohan ML. Advances in the systemic treatment of cutaneous sarcomas. Semin Oncol. 2012;39(2):173–83.CrossRefPubMed
41.
Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679–89.CrossRefPubMed
42.
Harding-Jackson N, Sangueza M, Mackinnon A, Suster S, Plaza JA. Spindle cell atypical fibroxanthoma: Myofibroblastic differentiation represents a diagnostic pitfall in this variant of afx. Am J Dermatopathol. 2015;37(7):509–14. quiz 515 – 506.CrossRefPubMed
43.
Fernandez-Flores A, Monteagudo C. Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas. Ann Diagn Pathol. 2016;24:25–9.CrossRefPubMed
44.
Idriss MH, Elston DM. S100a6 expression in cutaneous smooth muscle neoplasms. APMIS. 2015;123(10):832–6.CrossRefPubMed
45.
Suster S, Rosen LB, Sanchez JL. Granular cell leiomyosarcoma of the skin. Am J Dermatopathol. 1988;10(3):234–9.CrossRefPubMed
46.
Suster S. Epithelioid leiomyosarcoma of the skin and subcutaneous tissue. Clinicopathologic, immunohistochemical, and ultrastructural study of five cases. Am J Surg Pathol. 1994;18(3):232–40.CrossRefPubMed
47.
Diaz-Cascajo C, Borghi S, Weyers W. Desmoplastic leiomyosarcoma of the skin. Am J Dermatopathol. 2000;22(3):251–5.CrossRefPubMed
48.
Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: Clinicopathologic analysis of 84 cases and a reappraisal of cutaneous “leiomyosarcoma”. Am J Surg Pathol. 2011;35(4):599–607.CrossRefPubMed
49.
Coindre JM, Trojani M, Contesso G, David M, Rouesse J, Bui NB, et al. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer. 1986;58(2):306–9.CrossRefPubMed
50.
Group ESESNW. Soft tissue and visceral sarcomas: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii102–112.CrossRef
51.
Roberge D, Hickeson M, Charest M, Turcotte RE. Initial mcgill experience with fluorodeoxyglucose pet/ct staging of soft-tissue sarcoma. Curr Oncol. 2010;17(6):18–22.CrossRefPubMedPubMedCentral
52.
53.
Tsutsumida A, Yoshida T, Yamamoto Y, Itoh T, Minakawa H, Sugihara T. Management of superficial leiomyosarcoma: A retrospective study of 10 cases. Plast Reconstr Surg. 2005;116(1):8–12.CrossRefPubMed
54.
Starling J IIIrd, & Coldiron BM. Mohs micrographic surgery for the treatment of cutaneous leiomyosarcoma. J Am Acad Dermatol. 2011;64(6):1119–22.CrossRefPubMed
55.
McKee MD, Liu DF, Brooks JJ, Gibbs JF, Driscoll DL, Kraybill WG. The prognostic significance of margin width for extremity and trunk sarcoma. J Surg Oncol. 2004;85(2):68–76.CrossRefPubMed
56.
Humphreys TR, Finkelstein DH, Lee JB. Superficial leiomyosarcoma treated with mohs micrographic surgery. Dermatol Surg. 2004;30(1):108–12.PubMed
57.
Hollmig ST, Sachdev R, Cockerell CJ, Posten W, Chiang M, Kim J. Spindle cell neoplasms encountered in dermatologic surgery: A review. Dermatol Surg. 2012;38(6):825–50.CrossRefPubMed
58.
Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.CrossRefPubMed
59.
Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase ii/phase iii study of the eortc soft tissue and bone sarcoma group. Eur J Cancer Clin Oncol. 1987;23(10):1477–83.CrossRefPubMed
60.
Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: An open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488–97.CrossRefPubMedPubMedCentral
61.
Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, et al. Phase ii study of et-743 in advanced soft tissue sarcomas: A european organisation for the research and treatment of cancer (eortc) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23(3):576–84.CrossRefPubMed
62.
Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase ii and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22(8):1480–90.CrossRefPubMed
63.
von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, et al. Phase 2 southwest oncology group-directed intergroup trial (s0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012;118(3):770–6.CrossRef
64.
D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (alliance a091401): Two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416–26.CrossRefPubMed
65.
D’Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, et al. Prevalence of tumor-infiltrating lymphocytes and pd-l1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46(3):357–65.CrossRefPubMed
66.
67.
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (sarc028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–501.CrossRefPubMed
68.
Liao WC, Wang YC, Ma H. Cutaneous leiomyosarcoma: The clinical experience of taipei veterans general hospital revisited. Ann Plast Surg. 2017;78(3 Suppl 2):47-s51.
Metadata
Title
Primary leiomyosarcoma of the skin: a comprehensive review on diagnosis and treatment
Authors
Martina Zacher
Markus V. Heppt
Titus J. Brinker
Kinan M. Hayani
Michael J. Flaig
Carola Berking
Publication date
01-10-2018
Publisher
Springer US
Published in
Medical Oncology / Issue 10/2018
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-018-1196-2

Other articles of this Issue 10/2018

Medical Oncology 10/2018 Go to the issue

Original Paper

Pre-therapy CT scan showing peritoneal thickening from metastatic renal pelvis carcinoma patients

Review Article

Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy

Original Paper

Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study

Original Paper

Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma

Short Communication

Sorafenib in patients with progressed and refractory bone tumors

Review Article

Patient performance status and cancer immunotherapy efficacy: a meta-analysis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits